TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-03-31 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-20 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-14 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-11 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | 0.00% 10-K · filed 2019-03-25 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-13 | 0.00% 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-25 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-13 | 0.00% 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |